Free Trial
TSE:REUN

Reunion Neuroscience (REUN) Stock Price, News & Analysis

Reunion Neuroscience logo

About Reunion Neuroscience Stock (TSE:REUN)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
339 shs
Average Volume
12,447 shs
Market Capitalization
C$16.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company, develops therapeutic solutions for mental health conditions in North America. The company's lead asset includes RE104, a clinical-stage serotonergic psychedelic therapeutic product for antidepressant applications. It is also developing the RE200 series, which comprises molecules that are structurally designed to be similar to classical psychedelics with selective potency at the target serotonin 2A receptor (5HT2A) for potential chronic treatment in various patient populations and indications. The company was formerly known as Field Trip Health Ltd. Reunion Neuroscience Inc. was founded in 2008 and is headquartered in Toronto, Canada.

Receive REUN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reunion Neuroscience and its competitors with MarketBeat's FREE daily newsletter.

REUN Stock News Headlines

Why are so many Roman statues headless?
Volatility Is Rising—But These 2 AI Stocks Could Thrive
2025 is off to a turbulent start—markets are swinging wildly, inflation pressures remain high, and recession fears are creeping back into headlines. But even in uncertain times, innovation doesn’t slow down. In fact, artificial intelligence (AI) is accelerating faster than ever—creating new profit opportunities while the broader market struggles. Our latest research reveals two AI stocks trading under $15 that could thrive even as volatility grows. These under-the-radar companies are positioned to ride the next wave of AI-driven demand—and they’re still flying below most investors’ radar.
See More Headlines

REUN Stock Analysis - Frequently Asked Questions

Shares of REUN stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Reunion Neuroscience investors own include Meta Platforms (META) and BioLineRx (BLRX).

Industry, Sector and Symbol

Stock Exchange
TSE
Sector
Medical
Industry
Biotechnology
Sub-Industry
Healthcare
Current Symbol
TSE:REUN
CIK
N/A
Fax
N/A
Employees
190
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-C$38.10 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$4.86 million
Price / Cash Flow
N/A
Book Value
C$1.82 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
C$16.64 million
Optionable
Not Optionable
Beta
4.20
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (TSE:REUN) was last updated on 5/27/2025 by MarketBeat.com Staff
From Our Partners